医学临床研究
   May. 5, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2025, Vol. 42 Issue (3): 450-452    DOI: 10.3969/j.issn.1671-7171.2025.03.024
Current Issue | Archive | Adv Search |
Effect of Rabeprazole Combined with Mosapride on Gastric Motility Indicators and Gastrointestinal Hormones in Patients with Functional Dyspepsia
CHEN Xianle, XU Feng
Department of Internal Medicine, Xinghai Hospital, Suzhou Industrial Park, Suzhou Jiangsu 215000
Download: PDF (1175 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】 To explore the effects of rabeprazole combined with mosapride on gastric emptying rate, intestinal emptying rate, gastric motility indicators, and gastrointestinal hormones in patients with functional dyspepsia (FD).【Methods】 A total of 102 patients with FD were randomly divided into two groups: the observation group and the control group, with 51 patients in each group. Patients in the control group received only rabeprazole treatment, while the observation group was treated with rabeprazole combined with mosapride. The gastric emptying rate, intestinal emptying rate, gastric motility indicators [plasma leptin (LEP), motilin (MTL), corticotropin-releasing hormone (CRH)], and gastrointestinal hormones [gastrin (GAS), substance P (SP), vasoactive intestinal peptide (VIP)] levels were compared between the two groups before and after treatment. The incidence of adverse reactions was also recorded and compared.【Results】 After treatment, the observation group showed significantly better gastric emptying rate, intestinal emptying rate, gastric motility indicators, and gastrointestinal hormone levels compared to the control group (P<0.05). The total incidence of adverse reactions in the observation group was 5.88% (3/51), significantly lower than that of the control group at 19.61% (10/51), with a statistically significant difference (P<0.05).【Conclusion】 Rabeprazole combined with mosapride can significantly improve gastric and intestinal emptying rates, gastric motility, and gastrointestinal hormone levels in FD patients, while reducing the incidence of adverse reactions. It is worthy of clinical promotion and application.
Key wordsDyspepsia      Rabeprazole      Drug Therapy, Combination      Gastrointestinal Motility     
Received: 28 August 2024     
PACS:  R573  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
CHEN Xianle
XU Feng
Cite this article:   
CHEN Xianle,XU Feng. Effect of Rabeprazole Combined with Mosapride on Gastric Motility Indicators and Gastrointestinal Hormones in Patients with Functional Dyspepsia[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 450-452.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.03.024     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I3/450
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech